Address correspondence to Dr Jonathan M. Schott, Dementia Research Centre, UCL Queen Square Institute of Neurology, Box 16, Queen Square, London WC1N 3BG, UK, email@example.com.
RELATIONSHIP DISCLOSURE: Dr Schott serves on advisory boards for Biogen; Eli Lilly and Company; F Hoffman-La Roche Ltd; and Merck & Co, Inc, and on the drug safety monitoring board for AXON Neuroscience SE. Dr Schott has received personal compensation for speaking engagements for Biogen, Eli Lilly and Company, and GE Healthcare Worldwide and receives research/grant support from Alzheimer’s Research UK, Avid Radiopharmaceuticals, Brain Research UK, British Heart Foundation, Engineering and Physical Sciences Research Council (EP/J020990/1), European Commission Horizon 2020, Medical Research Council Dementias Platform UK (MR/L023784/1), Weston Brain Institute, and Wolfson Foundation. Dr Schott receives royalties from Henry Stewart Talks and Oxford University Press. Dr Crutch receives research/grant support from the Continued on page 75Alzheimer’s Society, (AS-PG-14-022), The Dunhill Medical Trust (R337/0214), the Economic and Social Research Council-National Institute for Health Research (ES/L001810/1), and the Engineering and Physical Sciences Research Council (EP/M006093/1).
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Drs Schott and Crutch report no disclosures.